Mitochondrial microRNAs Are Dysregulated in Patients with Fabry Disease

Fabry disease (FD) is a lysosomal storage disorder caused by mutations in the gene for α-galactosidase A, inducing a progressive accumulation of globotriaosylceramide (GB3) and its metabolites in different organs and tissues. GB3 deposition does not fully explain the clinical manifestations of FD, and other pathogenetic mechanisms have been proposed, requiring the identification of new biomarkers for monitoring FD patients. Emerging evidence suggests the involvement of mitochondrial alterations in FD. Here, we propose mitochondrial-related microRNAs (miRs) as potential biomarkers of mitochondrial involvement in FD. Indeed, we demonstate that miRs regulating different aspects of mitochondrial homeostasis including expression and assembly of respiratory chain, mitogenesis, antioxidant capacity, and apoptosis are consistently dysregulated in FD patients. Our data unveil a novel noncoding RNA signature of FD patients, indicating mitochondrial-related miRs as new potential pathogenic players and biomarkers in FD. SIGNIFICANCE STATEMENT This study demonstrates for the first time that a specific signature of circulating mitochondrial miRs (mitomiRs) is dysregulated in FD patients. MitomiRs regulating fundamental aspects of mitochondrial homeostasis and fitness, including expression and assembly of the respiratory chain, mitogenesis, antioxidant capacity, and apoptosis are significantly dysregulated in FD patients. Taken together, these new findings introduce mitomiRs as unprecedented biomarkers of FD and point at mitochondrial dysfunction as a novel potential mechanistic target for therapeutic approaches.

[1]  G. Santulli,et al.  Functional Role of microRNAs in Regulating Cardiomyocyte Death , 2022, Cells.

[2]  C. Maack,et al.  Mitochondria as Therapeutic Targets in Heart Failure , 2022, Current Heart Failure Reports.

[3]  G. Santulli,et al.  Glycation of ryanodine receptor in circulating lymphocytes predicts the response to cardiac resynchronization therapy. , 2021, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[4]  M. Ferracin,et al.  Circulating miR-184 is a potential predictive biomarker of cardiac damage in Anderson–Fabry disease , 2021, Cell Death & Disease.

[5]  M. Brandi,et al.  MicroRNAs as Potential Biomarkers in Pituitary Adenomas , 2021, Non-coding RNA.

[6]  A. Coppola,et al.  Role of endothelial miR-24 in COVID-19 cerebrovascular events , 2021, Critical Care.

[7]  J. Wojta,et al.  MiRNA Let-7a and Let-7d Are Induced by Globotriaosylceramide via NF-kB Activation in Fabry Disease , 2021, Genes.

[8]  M. Lenassi,et al.  Urinary Extracellular Vesicles and Their miRNA Cargo in Patients with Fabry Nephropathy , 2021, Genes.

[9]  V. Parra,et al.  Mitochondrial function, dynamics and quality control in the pathophysiology of HFpEF. , 2021, Biochimica et biophysica acta. Molecular basis of disease.

[10]  Xinxing Wang,et al.  Regulation of Mitochondrial Function by Noncoding RNAs in Heart Failure and Its Application in Diagnosis and Treatment , 2021, Journal of cardiovascular pharmacology.

[11]  A. Lymperopoulos,et al.  Impact of Aldosterone on the Failing Myocardium: Insights from Mitochondria and Adrenergic Receptors Signaling and Function , 2021, Cells.

[12]  Xiang-chun Shen,et al.  MicroRNAs Regulating Mitochondrial Function in Cardiac Diseases , 2021, Frontiers in Pharmacology.

[13]  P. Pinton,et al.  Mitochondrial Bioenergetics and Dynamism in the Failing Heart , 2021, Life.

[14]  G. Santulli,et al.  miR-24 Targets the Transmembrane Glycoprotein Neuropilin-1 in Human Brain Microvascular Endothelial Cells , 2021, Non-coding RNA.

[15]  J. Blusztajn,et al.  MicroRNAs as Candidate Biomarkers for Alzheimer’s Disease , 2021, Non-coding RNA.

[16]  D. Sorriento,et al.  The Cardiovascular Phenotype in Fabry Disease: New Findings in the Research Field , 2021, International journal of molecular sciences.

[17]  N. Sousa,et al.  Fabry Disease Therapy: State-of-the-Art and Current Challenges , 2020, International journal of molecular sciences.

[18]  P. Graziano,et al.  Non-Coding RNAs as Prognostic Biomarkers: A miRNA Signature Specific for Aggressive Early-Stage Lung Adenocarcinomas , 2020, Non-coding RNA.

[19]  A. Tuttolomondo,et al.  Biomarkers in Anderson–Fabry Disease , 2020, International journal of molecular sciences.

[20]  D. Sorriento,et al.  Role of Endothelial G Protein-Coupled Receptor Kinase 2 in Angioedema , 2020, Hypertension.

[21]  S. Feriozzi,et al.  Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data , 2020, European Journal of Human Genetics.

[22]  F. Weidemann,et al.  Diagnosis and Screening of Patients with Fabry Disease , 2020, Therapeutics and clinical risk management.

[23]  N. Dahms,et al.  Progress in the understanding and treatment of Fabry disease. , 2020, Biochimica et biophysica acta. General subjects.

[24]  Lubo Zhang,et al.  Mitochondrial MiRNA in Cardiovascular Function and Disease , 2019, Cells.

[25]  P. Nordbeck,et al.  Circulating microRNAs in Fabry Disease , 2019, Scientific Reports.

[26]  R. Schiffmann,et al.  Symptoms and Quality of Life in Patients with Fabry Disease: Results from an International Patient Survey , 2019, Advances in Therapy.

[27]  S. Booth,et al.  MicroRNAs in Neuroinflammation: Implications in Disease Pathogenesis, Biomarker Discovery and Therapeutic Applications , 2019, Non-coding RNA.

[28]  A. Kriegel,et al.  miR-21-5p regulates mitochondrial respiration and lipid content in H9C2 cells. , 2019, American journal of physiology. Heart and circulatory physiology.

[29]  E. Riccio,et al.  A pilot study of circulating microRNAs as potential biomarkers of Fabry disease , 2018, Oncotarget.

[30]  A. Andrade,et al.  Influence of exercise on oxidative stress in patients with heart failure , 2018, Heart Failure Reviews.

[31]  S. Feriozzi,et al.  Contribution of inflammatory pathways to Fabry disease pathogenesis. , 2017, Molecular genetics and metabolism.

[32]  Xiaoxia Wang,et al.  Mitochondria Associated MicroRNA Expression Profiling of Heart Failure , 2017, BioMed research international.

[33]  C. Melon,et al.  Inhibition of the Mitochondrial Glutamate Carrier SLC25A22 in Astrocytes Leads to Intracellular Glutamate Accumulation , 2017, Front. Cell. Neurosci..

[34]  Lang Li,et al.  MiR-486 regulates cardiomyocyte apoptosis by p53-mediated BCL-2 associated mitochondrial apoptotic pathway , 2017, BMC Cardiovascular Disorders.

[35]  G. Tiscornia,et al.  Mitochondrial Dysfunction in Lysosomal Storage Disorders , 2016, Diseases.

[36]  D. Lockhart,et al.  Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. , 2016, The New England journal of medicine.

[37]  A. Longo,et al.  Asymmetric dimethylarginine is transported by the mitochondrial carrier SLC25A2 , 2016, Amino Acids.

[38]  Gaetano Santulli,et al.  Mitochondrial calcium overload is a key determinant in heart failure , 2015, Proceedings of the National Academy of Sciences.

[39]  Sabine C. Mueller,et al.  miRNAs can be generally associated with human pathologies as exemplified for miR-144* , 2014, BMC Medicine.

[40]  G. Paolisso,et al.  Functional role of miRNA in cardiac resynchronization therapy. , 2014, Pharmacogenomics.

[41]  Yi Zhang,et al.  MicroRNA Directly Enhances Mitochondrial Translation during Muscle Differentiation , 2014, Cell.

[42]  G. Condorelli,et al.  Atrial fibrillation and microRNAs , 2014, Front. Physiol..

[43]  M. Kimura,et al.  MiR-184 regulates insulin secretion through repression of Slc25a22 , 2013, PeerJ.

[44]  J. Oliveira,et al.  Fibrosis: a key feature of Fabry disease with potential therapeutic implications , 2013, Orphanet Journal of Rare Diseases.

[45]  G. Burton,et al.  Suppression of Mitochondrial Electron Transport Chain Function in the Hypoxic Human Placenta: A Role for miRNA-210 and Protein Synthesis Inhibition , 2013, PloS one.

[46]  M. Sabbatini,et al.  Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature. , 2012, Molecular genetics and metabolism.

[47]  Sarah J. Wheelan,et al.  Nuclear miRNA Regulates the Mitochondrial Genome in the Heart , 2012, Circulation research.

[48]  M. Latronico,et al.  The might of microRNA in mitochondria. , 2012, Circulation Research.

[49]  P. Brugada,et al.  Globotriaosylsphingosine Accumulation and Not Alpha-Galactosidase-A Deficiency Causes Endothelial Dysfunction in Fabry Disease , 2012, PloS one.

[50]  B. Prabhakar,et al.  Control of mitochondrial activity by miRNAs , 2012, Journal of cellular biochemistry.

[51]  M. Ciccarelli,et al.  G protein-coupled receptor kinase 2 in patients with acute myocardial infarction. , 2011, The American journal of cardiology.

[52]  Jiayou Zhang,et al.  miR-17* Suppresses Tumorigenicity of Prostate Cancer by Inhibiting Mitochondrial Antioxidant Enzymes , 2010, PloS one.

[53]  G. Shulman,et al.  Regulation of mitochondrial biogenesis. , 2010, Essays in biochemistry.

[54]  Y. Naito,et al.  The microRNA miR-696 regulates PGC-1{alpha} in mouse skeletal muscle in response to physical activity. , 2010, American journal of physiology. Endocrinology and metabolism.

[55]  C. Steer,et al.  MicroRNAs identified in highly purified liver-derived mitochondria may play a role in apoptosis , 2009, RNA biology.

[56]  A. Aschrafi,et al.  MicroRNA-338 Regulates Local Cytochrome c Oxidase IV mRNA Levels and Oxidative Phosphorylation in the Axons of Sympathetic Neurons , 2008, The Journal of Neuroscience.

[57]  A. Das,et al.  Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts. , 2004, Molecular genetics and metabolism.

[58]  B. Schermer,et al.  Enzyme Replacement Therapy Clears Gb3 Deposits from a Podocyte Cell Culture Model of Fabry Disease but Fails to Restore Altered Cellular Signaling. , 2019, Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology.

[59]  Quincy A. Hathaway,et al.  Role of microRNA in metabolic shift during heart failure. , 2017, American journal of physiology. Heart and circulatory physiology.

[60]  G. Santulli,et al.  Mechanistic Role of MicroRNAs in Coupling Lipid Metabolism and Atherosclerosis. , 2015, Advances in experimental medicine and biology.

[61]  G. Santulli,et al.  MicroRNA: From Molecular Biology to Clinical Practice , 2015 .

[62]  G. Santulli Exploiting microRNA Specificity and Selectivity: Paving a Sustainable Path Towards Precision Medicine. , 2015, Advances in experimental medicine and biology.

[63]  P. Luna,et al.  [Fabry disease]. , 2009, Anais brasileiros de dermatologia.

[64]  H. Naim,et al.  Biochemical basis of Fabry disease with emphasis on mitochondrial function and protein trafficking. , 2009, Advances in clinical chemistry.

[65]  R. Desnick,et al.  Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. , 2001, American journal of human genetics.

[66]  J. Schmidt Comparative studies on the anticonvulsant effectiveness of nootropic drugs in kindled rats. , 1990, Biomedica biochimica acta.